Compare DexCom, Inc. (DXCM) vs Nordic American Tankers Limited Common Stock (NAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nordic American Tankers Limited Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Nordic American Tankers Limited Common Stock trades at $8.2 (market cap $1.86B). The key difference: DexCom, Inc. is far larger — about 17.3× Nordic American Tankers Limited Common Stock's market cap, and Nordic American Tankers Limited Common Stock pays a 12.29% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nordic American Tankers Limited Common Stock for 0 Days on average.
| DXCM | NAT | |
|---|---|---|
Market Cap | $32.09B | $1.86B |
Volume | 3,819,730 | 5,330,493 |
Sector | Health | Industrials |
52-Week High | $92.34 | $8.79 |
52-Week Low | $54.84 | $3.26 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $2.13B |
Dividend Yield | — | 12.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
NAT trades at $8.79, matching its 52-week high, reflecting strong momentum amid favorable tanker market conditions. The stock shows robust fundamentals with a 33.34% net income margin and 25.66% ROE for 2026, while Q2 2026 EPS beat expectations. Technical indicators are neutral, with support and resistance clustered around $9. Recent news highlights surging spot rates and insider buying by the Hansson family, underscoring confidence in near-term prospects.
Outlook is positive due to elevated freight rates and earnings growth, but risks include volatility in tanker rates and geopolitical tensions. Analysts are mixed with a $3.50 consensus target, suggesting caution despite operational strength. The stock's high yield and momentum offer appeal, though sustainability of current rates remains a key monitorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nordic American Tankers Limited Common Stock
Nordic American Tankers Limited is a Bermuda-based shipping company specializing exclusively in Suezmax crude-oil tankers, which it charters in the spot and period markets on international routes. The company has paid a dividend every quarter since 1997.
Read more on NAT →
